| __timestamp | Exelixis, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 46425000 |
| Thursday, January 1, 2015 | 96351000 | 81491000 |
| Friday, January 1, 2016 | 95967000 | 94291000 |
| Sunday, January 1, 2017 | 112171000 | 121827000 |
| Monday, January 1, 2018 | 182257000 | 160524000 |
| Tuesday, January 1, 2019 | 336964000 | 200000000 |
| Wednesday, January 1, 2020 | 547851000 | 275000000 |
| Friday, January 1, 2021 | 693716000 | 328100000 |
| Saturday, January 1, 2022 | 891813000 | 463800000 |
| Sunday, January 1, 2023 | 1044071000 | 565000000 |
| Monday, January 1, 2024 | 910408000 | 731100000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) investments are crucial for innovation and growth. Over the past decade, Neurocrine Biosciences, Inc. and Exelixis, Inc. have demonstrated significant commitment to R&D, with Exelixis leading the charge. From 2014 to 2023, Exelixis increased its R&D spending by over 450%, reaching a peak in 2023. Neurocrine Biosciences, while starting from a lower base, also showed a robust growth of approximately 1,100% in the same period.
This trend highlights the strategic focus of these companies on developing new therapies and maintaining a competitive edge. The data underscores the importance of sustained investment in R&D for biotech firms aiming to drive innovation and deliver breakthrough treatments. As the industry continues to evolve, these investments will likely play a pivotal role in shaping the future of healthcare.
Comparing Innovation Spending: Amgen Inc. and Neurocrine Biosciences, Inc.
Comparing Innovation Spending: Neurocrine Biosciences, Inc. and Alkermes plc
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Rhythm Pharmaceuticals, Inc.
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
R&D Spending Showdown: Neurocrine Biosciences, Inc. vs Vericel Corporation
Who Prioritizes Innovation? R&D Spending Compared for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Neurocrine Biosciences, Inc. vs Dynavax Technologies Corporation: Strategic Focus on R&D Spending
R&D Insights: How Exelixis, Inc. and CymaBay Therapeutics, Inc. Allocate Funds
Exelixis, Inc. or Corcept Therapeutics Incorporated: Who Invests More in Innovation?
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Investment: Exelixis, Inc. vs Alkermes plc
R&D Insights: How Exelixis, Inc. and Amicus Therapeutics, Inc. Allocate Funds